After years of hard working, Creative Biolabs is now in a leading position of antibody discovery and immunotherapy. We can provide a new kind of CAR-T cells which can express PD-1 antibody and thus enhance the safety and specificity of CAR-T cell therapy. This kind of CAR-T cells overcomes the limitation on the treatment of solid tumor by combining CAR-T cells with checkpoint blockade.
Chimeric antigen receptors (CAR) are engineering proteins expressed on the surface of immune cells to interact with the target tumor cells. In recent years, CAR has been successful induced into T cells and contributes to the therapy of tumors. The mechanism lies in the combination of CAR antigen-binding ability and T cell activation capability. Another vital participator of the immune system is immune checkpoints, which usually function as regulators. For this character, it has been regarded as a new immunotherapy method for tumor. The inhibitor members include CTLA4 and PD-1 and PD-L1, among which PD-1 inhibitor can be used to treat lots of solid tumors, including melanoma, lung cancer, kidney cancer, bladder cancer, head, and neck cancer.
Introduction of CAR-T Cells With PD-1 Antibody
Although CAR-T cells have got great progress in the treatment of some blood tumor, they don’t show outstanding outcomes in solid tumor therapy. The checkpoint inhibitor has brilliant performance in this field, however, it is disturbed by side-effect. CAR-T cells expressed with PD-1 antibody is the production of loading checkpoint inhibitor on CAR-T cells. By this way, we try to overcome the side-effect by the stimulation of CAR-T cells. This newly designed cell can release a small protein scFv, which can bind with PD-1. Its function will theoretically contribute to tumor therapy via promoting the activity of immune cells. We conduct an experiment on solid tumor model mice and get the conclusion that these new T cells have more outstanding behavior in prolonging survival rate. As the scFv is directly released into the tumor, it will easily trigger the activation of other nearby T cells. We also detected the concentration of the released inhibitor in the circulatory system and found that it closely maintains around the tumor tissue, which demonstrates a low frequency of side-effect.
Fig.1 Factors influencing CAR T-cell activity in the immunosuppressive solid tumor microenvironment. (Marcela V. Maus.; Carl H. 2016)
Highlight Features of Our Service
With years of research by our professional and experienced team, Creative Biolabs has gained rich experience in the field of immunotherapy. We keep in cooperation with customer and get a good reputation around the world. It is our pleasure to provide timely support and guarantee smoothly circulation of your projects. We are dedicated to facilitating your projects and pushing the progress towards clinical trials through sharing our technologies, platforms, and resources. If you have any questions, please feel free to contact us for more information, we will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE